Racetam research medicine · Fact sheet
Piracetam
Also known as Nootropil
Piracetam is a racetam with historical human studies in neurologic disorders. Some small studies report task or rehabilitation benefits, but they do not establish reliable cognitive enhancement in healthy people.
What is Piracetam?
Piracetam is a small molecule, despite being discussed alongside peptide nootropics.
Post-stroke rehabilitation, postoperative cognition and healthy-person performance are different questions.
Benefits & claims
Readers encounter Piracetam in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.
What the evidence supports
- The aphasia study found improved language-related measures with concomitant intensive speech therapy.
- The cardiac-surgery analysis depends on the analyzed population and needs replication.
- These results do not establish a universal memory benefit or replacement for rehabilitation.
Research areas
- Cognition and memory
- Neurologic or psychiatric research
Dosage & frequency
Human study contextThe original human study supplies an exposure reference, not an established cognitive-enhancement regimen.
Post-stroke aphasia randomized study
24 stroke patients with aphasia receiving intensive speech therapy
- Amount
- 2,400 mg
- Frequency
- Twice daily for six weeks
- Route studied or labeled
- Oral
This was adjunctive rehabilitation research, not healthy-person memory enhancement. The small study does not establish a general prescribing schedule.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Piracetam is a small molecule, despite being discussed alongside peptide nootropics.
Formulation differences
- Post-stroke rehabilitation, postoperative cognition and healthy-person performance are different questions.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Side effects & risks
- Safety cannot be generalized across neurologic diseases, kidney function, co-medications and the high doses used in some trials.
- The small studies cannot define uncommon harms or safety of prolonged enhancement use.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceA 24-person aphasia study combined piracetam with intensive speech therapy. A separate 98-person cardiac-surgery study had a significant per-protocol result but not a conventionally significant intention-to-treat comparison.
Studies
24-person aphasia rehabilitation trial.
98-person CABG trial; per-protocol and intention-to-treat results differed.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 2 sourced accounts by reported effect.
Energy: reported experiences
Little sustained change despite a brief episode of stimulation
An author described little consistent benefit during two weeks of piracetam. One day brought brief enthusiasm and less presentation anxiety, followed by tiredness and a later burst of energy that felt excessive.
Reported use in this account
- Product
- Piracetam
- Amount
- 3.6 g total daily in the first week; 4.8 g total daily in the second week
- Frequency
- Daily; the initial daily amount was divided into three exposures
- Route
- Not specified clearly
- Duration
- Two weeks
Other exposures described: Coffee; Smoking
The author used coffee and smoked. One amount was a plan rather than a completed exposure, so it is not transcribed as consumed. Expectations and changing amounts make the experience difficult to interpret.
Read the original accountPerceived memory benefits with insomnia, anxiety and difficult discontinuation
A long-term author described better verbal fluency, memory and motivation, but also brain fog, insomnia and anxiety at amounts they had previously tolerated. They reported sleepiness, loss of pleasure and cognitive difficulty during an attempted discontinuation.
Reported use in this account
- Product
- Piracetam
- Amount
- Earlier 4 g daily; 1.4 g daily at the time of the account
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Five years
Other exposures described: Changing choline-related supplement and food exposures; Prior psychiatric-drug exposures described in replies
This single account cannot establish dependence, a mechanism, or interactions asserted elsewhere in the post. The author described changes in food and supplement exposures, and baseline symptoms could contribute to the discontinuation experience.
Read the original accountSleep: reported experiences
Perceived memory benefits with insomnia, anxiety and difficult discontinuation
A long-term author described better verbal fluency, memory and motivation, but also brain fog, insomnia and anxiety at amounts they had previously tolerated. They reported sleepiness, loss of pleasure and cognitive difficulty during an attempted discontinuation.
Reported use in this account
- Product
- Piracetam
- Amount
- Earlier 4 g daily; 1.4 g daily at the time of the account
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Five years
Other exposures described: Changing choline-related supplement and food exposures; Prior psychiatric-drug exposures described in replies
This single account cannot establish dependence, a mechanism, or interactions asserted elsewhere in the post. The author described changes in food and supplement exposures, and baseline symptoms could contribute to the discontinuation experience.
Read the original accountMood: reported experiences
Little sustained change despite a brief episode of stimulation
An author described little consistent benefit during two weeks of piracetam. One day brought brief enthusiasm and less presentation anxiety, followed by tiredness and a later burst of energy that felt excessive.
Reported use in this account
- Product
- Piracetam
- Amount
- 3.6 g total daily in the first week; 4.8 g total daily in the second week
- Frequency
- Daily; the initial daily amount was divided into three exposures
- Route
- Not specified clearly
- Duration
- Two weeks
Other exposures described: Coffee; Smoking
The author used coffee and smoked. One amount was a plan rather than a completed exposure, so it is not transcribed as consumed. Expectations and changing amounts make the experience difficult to interpret.
Read the original accountPerceived memory benefits with insomnia, anxiety and difficult discontinuation
A long-term author described better verbal fluency, memory and motivation, but also brain fog, insomnia and anxiety at amounts they had previously tolerated. They reported sleepiness, loss of pleasure and cognitive difficulty during an attempted discontinuation.
Reported use in this account
- Product
- Piracetam
- Amount
- Earlier 4 g daily; 1.4 g daily at the time of the account
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Five years
Other exposures described: Changing choline-related supplement and food exposures; Prior psychiatric-drug exposures described in replies
This single account cannot establish dependence, a mechanism, or interactions asserted elsewhere in the post. The author described changes in food and supplement exposures, and baseline symptoms could contribute to the discontinuation experience.
Read the original accountFocus: reported experiences
Little sustained change despite a brief episode of stimulation
An author described little consistent benefit during two weeks of piracetam. One day brought brief enthusiasm and less presentation anxiety, followed by tiredness and a later burst of energy that felt excessive.
Reported use in this account
- Product
- Piracetam
- Amount
- 3.6 g total daily in the first week; 4.8 g total daily in the second week
- Frequency
- Daily; the initial daily amount was divided into three exposures
- Route
- Not specified clearly
- Duration
- Two weeks
Other exposures described: Coffee; Smoking
The author used coffee and smoked. One amount was a plan rather than a completed exposure, so it is not transcribed as consumed. Expectations and changing amounts make the experience difficult to interpret.
Read the original accountPerceived memory benefits with insomnia, anxiety and difficult discontinuation
A long-term author described better verbal fluency, memory and motivation, but also brain fog, insomnia and anxiety at amounts they had previously tolerated. They reported sleepiness, loss of pleasure and cognitive difficulty during an attempted discontinuation.
Reported use in this account
- Product
- Piracetam
- Amount
- Earlier 4 g daily; 1.4 g daily at the time of the account
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Five years
Other exposures described: Changing choline-related supplement and food exposures; Prior psychiatric-drug exposures described in replies
This single account cannot establish dependence, a mechanism, or interactions asserted elsewhere in the post. The author described changes in food and supplement exposures, and baseline symptoms could contribute to the discontinuation experience.
Read the original accountNo clear change: reported experiences
Little sustained change despite a brief episode of stimulation
An author described little consistent benefit during two weeks of piracetam. One day brought brief enthusiasm and less presentation anxiety, followed by tiredness and a later burst of energy that felt excessive.
Reported use in this account
- Product
- Piracetam
- Amount
- 3.6 g total daily in the first week; 4.8 g total daily in the second week
- Frequency
- Daily; the initial daily amount was divided into three exposures
- Route
- Not specified clearly
- Duration
- Two weeks
Other exposures described: Coffee; Smoking
The author used coffee and smoked. One amount was a plan rather than a completed exposure, so it is not transcribed as consumed. Expectations and changing amounts make the experience difficult to interpret.
Read the original accountApproval status
Piracetam is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Summary
These results do not establish a universal memory benefit or replacement for rehabilitation.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedPiracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients.
24-person aphasia rehabilitation trial.
- pubmedPiracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo.
98-person CABG trial; per-protocol and intention-to-treat results differed.
- fdaFDA warning letter: unapproved nootropic claims
FDA identifies unapproved drug claims for named nootropics; this is an enforcement letter, not efficacy evidence.